Literature DB >> 16000112

Studies of the efficacy of Enterocoliticin, a phage-tail like bacteriocin, as antimicrobial agent against Yersinia enterocolitica serotype O3 in a cell culture system and in mice.

C Damasko1, A Konietzny, H Kaspar, B Appel, P Dersch, E Strauch.   

Abstract

The efficacy of enterocoliticin, a phage tail-like bacteriocin, as antimicrobial compound against infections with pathogenic Yersinia enterocolitica serotype O3 strains was assessed. In cell cultures, which were infected with the Y. enterocolitica strains 13 169 or 6471/76, bactericidal activity of enterocoliticin was found for bacteria adhering to the surface of eukaryotic cells, whereas bacteria, which had invaded the eukaryotic cells, were not accessible to the bacteriocin. The interaction of enterocoliticin with Y. enterocolitica was further examined in animals. Female BALB/c mice were experimentally infected with the two Y. enterocolitica strains and enterocoliticin was applied as antimicrobial compound by the oral route. Experimental variations concerning the infectious doses of the Y. enterocolitica strains and the time points of application of the bacteriocin were investigated. The increase of the Yersinia CFU titre in animals was retarded at time points shortly after the application of enterocoliticin indicating that the particles were effective on recently introduced Yersinia. The repeated application of enterocoliticin, however, did not prevent the colonization of the gastrointestinal tract by Yersinia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000112     DOI: 10.1111/j.1439-0450.2005.00841.x

Source DB:  PubMed          Journal:  J Vet Med B Infect Dis Vet Public Health        ISSN: 0931-1793


  9 in total

1.  Phage tail-like (high-molecular-weight) bacteriocins of Budvicia aquatica and Pragia fontium (Enterobacteriaceae).

Authors:  Jan Smarda; Oldrich Benada
Journal:  Appl Environ Microbiol       Date:  2005-12       Impact factor: 4.792

2.  Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile.

Authors:  Dana Gebhart; Steven R Williams; Kimberly A Bishop-Lilly; Gregory R Govoni; Kristin M Willner; Amy Butani; Shanmuga Sozhamannan; David Martin; Louis-Charles Fortier; Dean Scholl
Journal:  J Bacteriol       Date:  2012-09-14       Impact factor: 3.490

Review 3.  Functional viral metagenomics and the next generation of molecular tools.

Authors:  Thomas Schoenfeld; Mark Liles; K Eric Wommack; Shawn W Polson; Ronald Godiska; David Mead
Journal:  Trends Microbiol       Date:  2009-11-05       Impact factor: 17.079

4.  Gut proteases target Yersinia invasin in vivo.

Authors:  Janja Trček; Marc F Oellerich; Katy Niedung; Frank Ebel; Sandra Freund; Konrad Trülzsch
Journal:  BMC Res Notes       Date:  2011-04-18

5.  Unique activity spectrum of colicin FY: all 110 characterized Yersinia enterocolitica isolates were colicin FY susceptible.

Authors:  Juraj Bosák; Lenka Micenková; Martin Vrba; Alena Ševčíková; Daniela Dědičová; Debora Garzetti; David Šmajs
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

6.  Colicin FY inhibits pathogenic Yersinia enterocolitica in mice.

Authors:  Juraj Bosák; Lenka Micenková; Matěj Hrala; Katarína Pomorská; Michaela Kunova Bosakova; Pavel Krejci; Eduard Göpfert; Martin Faldyna; David Šmajs
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

7.  The therapeutic potential of bacteriocins as protein antibiotics.

Authors:  Hannah M Behrens; Anne Six; Daniel Walker; Colin Kleanthous
Journal:  Emerg Top Life Sci       Date:  2017-04-21

8.  The post-antibiotic era: promising developments in the therapy of infectious diseases.

Authors:  Mario Zucca; Dianella Savoia
Journal:  Int J Biomed Sci       Date:  2010-06

9.  The Yersinia Phage X1 Administered Orally Efficiently Protects a Murine Chronic Enteritis Model Against Yersinia enterocolitica Infection.

Authors:  Yibing Xue; Shengjie Zhai; Zijing Wang; Yalu Ji; Gang Wang; Tianqi Wang; Xinwu Wang; Hengyu Xi; Ruopeng Cai; Rihong Zhao; Hao Zhang; Lanting Bi; Yuan Guan; Zhimin Guo; Wenyu Han; Jingmin Gu
Journal:  Front Microbiol       Date:  2020-03-06       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.